"Transparent" DRG (Diagnosis Related Groups) still lacks clarity, claim German experts
This article was originally published in Clinica
Executive Summary
The new DRG (Diagnosis Related Groups) system will encourage transparency within the inpatient sector and make it possible to compare individual hospitals, but there are still many grey areas about Germany's future reimbursement system. This was the consensus at a special conference held by the industry association, BVMed, last week in Bonn. Delegates at the conference, entitled "The G-DRG system - a revolution in the German hospital market", were united that DRGs would not lead to cost savings in the sector.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.